In vivo antifungal activity and biocompatibility of Cryptocarya moschata

Arch Microbiol. 2022 Aug 20;204(9):569. doi: 10.1007/s00203-022-03177-1.

Abstract

The objective of this study was evaluate, in vivo model, the antifungal activity of Cryptocarya moschata extract against Candida albicans and its biocompatibility. The animals (N = 50) were divided into groups (n = 5): CI/CG: candidiasis was induced and treated with C. moschata extract (0.045 g/mL); CI/NG: candidiasis was induced and treated with nystatin; CI/NT: candidiasis was induced and no treated; CI/CG-2: candidiasis was induced and treated with C. moschata extract (0.045 g/mL), reapplied after 24 h; CI/NG-2: candidiasis was induced and treated with nystatin, reapplied after 24 h; NCI/NT: candidiasis was not induced and no treated; NCI/CG: candidiasis was not induced and treated with C. moschata extract (0.045 g/mL); NCI/NG: candidiasis was not induced treated with nystatin; NCI/CG-2: candidiasis was not induced and treated with C. moschata extract (0.045 g/mL), reapplied after 24 h; NCI/NG-2: candidiasis was not induced and treated with nystatin, reapplied after 24 h. The fungi present in the lingual dorsum of mice were collected and analyzed by the count of colony-forming units. In addition, histological analysis was performed. Histologically, there was no cell damage in the mice's tongue, and there was a decrease in Candida biofilm, similar to the use of nystatin. It was concluded that the C. moschata extract was effective against C. albicans and was biocompatible.

Keywords: Antifungal; Biocompatibility; Candidiasis; Medicinal plant.

MeSH terms

  • Animals
  • Antifungal Agents* / pharmacology
  • Antifungal Agents* / therapeutic use
  • Candida albicans
  • Cryptocarya*
  • Mice
  • Microbial Sensitivity Tests
  • Nystatin / pharmacology
  • Plant Extracts / pharmacology

Substances

  • Antifungal Agents
  • Plant Extracts
  • Nystatin